These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2174642)

  • 61. Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy.
    Silva FM; Eisig JN; Teixeira AC; Barbuti RC; Navarro-Rodriguez T; Mattar R
    BMC Gastroenterol; 2008 May; 8():20. PubMed ID: 18510773
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antimicrobial activities of Eugenol and Cinnamaldehyde against the human gastric pathogen Helicobacter pylori.
    Ali SM; Khan AA; Ahmed I; Musaddiq M; Ahmed KS; Polasa H; Rao LV; Habibullah CM; Sechi LA; Ahmed N
    Ann Clin Microbiol Antimicrob; 2005 Dec; 4():20. PubMed ID: 16371157
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Diagnostic methods for Helicobacter pylori detection and eradication.
    Goddard AF; Logan RP
    Br J Clin Pharmacol; 2003 Sep; 56(3):273-83. PubMed ID: 12919175
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antibiotic resistance of Helicobacter pylori strains in Japanese children.
    Kato S; Fujimura S; Udagawa H; Shimizu T; Maisawa S; Ozawa K; Iinuma K
    J Clin Microbiol; 2002 Feb; 40(2):649-53. PubMed ID: 11825987
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection.
    Kanamaru T; Nakano Y; Toyoda Y; Miyagawa KI; Tada M; Kaisho T; Nakao M
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2455-9. PubMed ID: 11502514
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children.
    Kalach N; Bergeret M; Benhamou PH; Dupont C; Raymond J
    J Clin Microbiol; 2001 Jan; 39(1):394-7. PubMed ID: 11136811
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene.
    Sisson G; Jeong JY; Goodwin A; Bryden L; Rossler N; Lim-Morrison S; Raudonikiene A; Berg DE; Hoffman PS
    J Bacteriol; 2000 Sep; 182(18):5091-6. PubMed ID: 10960092
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach.
    Dore MP; Leandro G; Realdi G; Sepulveda AR; Graham DY
    Dig Dis Sci; 2000 Jan; 45(1):68-76. PubMed ID: 10695616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Formulary management of antiulcer drugs: clinical considerations.
    Sankey SL; Friedman LS
    Pharmacoeconomics; 1994 Mar; 5(3):213-26. PubMed ID: 10146896
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.
    Buckley MJ; Xia HX; Hyde DM; Keane CT; O'Morain CA
    Dig Dis Sci; 1997 Oct; 42(10):2111-5. PubMed ID: 9365144
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risks related to lack of standardization of tests to detect in vitro metronidazole resistance in Helicobacter pylori.
    Henriksen TH; Brorson O; Schöyen R; Thoresen T
    Eur J Clin Microbiol Infect Dis; 1996 Jun; 15(6):484-8. PubMed ID: 8839643
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease.
    Rauws EA; van der Hulst RW
    Drugs; 1995 Dec; 50(6):984-90. PubMed ID: 8612476
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of time-kill methodology to assess antimicrobial combinations against metronidazole-susceptible and metronidazole-resistant strains of Helicobacter pylori.
    Coudron PE; Stratton CW
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2641-4. PubMed ID: 8592994
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.
    Jaskiewicz K; Louw JA; Marks IN
    Dig Dis Sci; 1993 May; 38(5):937-43. PubMed ID: 8482195
    [TBL] [Abstract][Full Text] [Related]  

  • 75. One week's anti-Helicobacter pylori treatment for duodenal ulcer.
    Logan RP; Gummett PA; Misiewicz JJ; Karim QN; Walker MM; Baron JH
    Gut; 1994 Jan; 35(1):15-8. PubMed ID: 8307442
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Indications for treatment of Helicobacter pylori infection: a systematic overview.
    Veldhuyzen van Zanten SJ; Sherman PM
    CMAJ; 1994 Jan; 150(2):189-98. PubMed ID: 8287341
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Helicobacter pylori and peptic ulcer disease.
    Feldman M; Peterson WL
    West J Med; 1993 Nov; 159(5):555-9. PubMed ID: 8279151
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The coccoid forms of Helicobacter pylori. Criteria for their viability.
    Bode G; Mauch F; Malfertheiner P
    Epidemiol Infect; 1993 Dec; 111(3):483-90. PubMed ID: 8270008
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori.
    van Zwet AA; Thijs JC; Schievink-de Vries W; Schiphuis J; Snijder JA
    Antimicrob Agents Chemother; 1994 Feb; 38(2):360-2. PubMed ID: 8192465
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of Helicobacter pylori-associated gastroduodenal disease in children. Clinical evaluation of antisecretory vs antibacterial therapy.
    Rosioru C; Glassman MS; Berezin SH; Bostwick HE; Halata M; Schwarz SM
    Dig Dis Sci; 1993 Jan; 38(1):123-8. PubMed ID: 8093598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.